ESLA
Estrella Immunopharma, Inc. · NASDAQ
- Sector Health Technology
- Industry Biotechnology
- Website estrellabio.com
- Employees(FY) -
- ISIN US2975841048
Performance
-5.14%
1W
-6.45%
1M
-7.73%
3M
-15.42%
6M
-8.56%
YTD
-90.71%
1Y
Profile
Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.
Technical Analysis of ESLA 2024-05-10
Overview:
In analyzing the technical indicators for ESLA over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement. By examining these key aspects, we aim to offer valuable insights and predictions for the upcoming trading days.
Trend An...
Recent News & Updates
- 2023-09-28 22:34
- 2023-09-18 05:00
- 2023-08-18 04:30
- 2023-07-18 04:30
- 2023-07-11 19:00
Page 1 of 1
previousnext